The estimated Net Worth of Kenneth Hoberman is at least 22.7 百万$ dollars as of 9 March 2020. Mr. Hoberman owns over 26,191 units of TG Therapeutics Inc stock worth over 17,804,595$ and over the last 11 years he sold TGTX stock worth over 4,606,522$. In addition, he makes 245,000$ as Independent Director at TG Therapeutics Inc.
Kenneth has made over 31 trades of the TG Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 26,191 units of TGTX stock worth 130,169$ on 9 March 2020.
The largest trade he's ever made was exercising 112,940 units of TG Therapeutics Inc stock on 22 November 2013 worth over 125,363$. On average, Kenneth trades about 10,697 units every 44 days since 2013. As of 9 March 2020 he still owns at least 771,764 units of TG Therapeutics Inc stock.
You can see the complete history of Mr. Hoberman stock trades at the bottom of the page.
Kenneth Hoberman serves as Independent Director of the Company. Mr. Hoberman is currently the Chief Operating Officer and Corporate Secretary of Stemline Therapeutics, Inc. where he was a key member of the founding team. He was instrumental in the company’s financings from early private, including institutional, rounds through the IPO and subsequent follow-on offerings. He has extensive financial, accounting, investor relations, corporate governance and business development experience including M&A, strategic alliances and partnerships both domestic and international. His operational expertise includes regulatory oversight, human resources, manufacturing and clinical development. He was previously Vice President of Corporate and Business Development of Keryx Biopharmaceuticals, Inc., where he was instrumental in the success of the company. He also helped secure multiple sources of capital including over $200 million in equity investments through public and private offerings. He also initiated and executed a $100 million strategic alliance and originated, negotiated and closed dozens of licensing and operational contracts, helping to grow the company’s market capitalization to over $1 billion. He also led the team that originated, in-licensed, and developed AuryxiaTM which recently gained FDA approval. He received a B.S.B.A. in Finance from Boston University and completed post-baccalaureate studies at Columbia University. Based on Mr. Hoberman’s financial and pharmaceutical industry experience and in-depth understanding of our business, as well as his extensive management experience, the Board of Directors believes that Mr. Hoberman has the appropriate set of skills to serve as a member of the Board.
As the Independent Director of TG Therapeutics Inc, the total compensation of Kenneth Hoberman at TG Therapeutics Inc is 245,000$. There are 5 executives at TG Therapeutics Inc getting paid more, with Michael Weiss having the highest compensation of 12,674,700$.
Kenneth Hoberman is 55, he's been the Independent Director of TG Therapeutics Inc since 2014. There are 3 older and 5 younger executives at TG Therapeutics Inc. The oldest executive at TG Therapeutics Inc is William Kennedy, 75, who is the Independent Director.
Kenneth's mailing address filed with the SEC is 3020 CARRINGTON MILL BLVD, SUITE 475, , MORRISVILLE, NC, 27560.
Over the last 13 years, insiders at TG Therapeutics Inc have traded over 23,556,837$ worth of TG Therapeutics Inc stock and bought 549,710 units worth 3,334,566$ . The most active insiders traders include Capital Management, L.P.Kol...、Michael S Weiss、Sean A Power. On average, TG Therapeutics Inc executives and independent directors trade stock every 107 days with the average trade being worth of 1,103,023$. The most recent stock trade was executed by Sagar Lonial on 17 June 2024, trading 25,933 units of TGTX stock currently worth 432,822$.
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
TG Therapeutics Inc executives and other stock owners filed with the SEC include: